Salarius Pharmaceuticals (SLRX) Competitors $1.45 -0.03 (-2.03%) (As of 11/4/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends SLRX vs. SNOA, MDVL, CDT, ABVC, ATHE, SNGX, RNAZ, UPXI, OBSV, and COEPShould you be buying Salarius Pharmaceuticals stock or one of its competitors? The main competitors of Salarius Pharmaceuticals include Sonoma Pharmaceuticals (SNOA), MedAvail (MDVL), Conduit Pharmaceuticals (CDT), ABVC BioPharma (ABVC), Alterity Therapeutics (ATHE), Soligenix (SNGX), TransCode Therapeutics (RNAZ), Upexi (UPXI), ObsEva (OBSV), and Coeptis Therapeutics (COEP). Salarius Pharmaceuticals vs. Sonoma Pharmaceuticals MedAvail Conduit Pharmaceuticals ABVC BioPharma Alterity Therapeutics Soligenix TransCode Therapeutics Upexi ObsEva Coeptis Therapeutics Salarius Pharmaceuticals (NASDAQ:SLRX) and Sonoma Pharmaceuticals (NASDAQ:SNOA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, community ranking, media sentiment, profitability, dividends, valuation, analyst recommendations and institutional ownership. Which has more volatility and risk, SLRX or SNOA? Salarius Pharmaceuticals has a beta of 0.93, meaning that its share price is 7% less volatile than the S&P 500. Comparatively, Sonoma Pharmaceuticals has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500. Which has higher earnings and valuation, SLRX or SNOA? Sonoma Pharmaceuticals has higher revenue and earnings than Salarius Pharmaceuticals. Sonoma Pharmaceuticals is trading at a lower price-to-earnings ratio than Salarius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSalarius Pharmaceuticals$1.84M1.13-$12.54M-$12.61-0.11Sonoma Pharmaceuticals$12.73M0.21-$4.84M-$10.20-0.27 Does the MarketBeat Community favor SLRX or SNOA? Sonoma Pharmaceuticals received 190 more outperform votes than Salarius Pharmaceuticals when rated by MarketBeat users. Likewise, 67.50% of users gave Sonoma Pharmaceuticals an outperform vote while only 54.17% of users gave Salarius Pharmaceuticals an outperform vote. CompanyUnderperformOutperformSalarius PharmaceuticalsOutperform Votes2654.17% Underperform Votes2245.83% Sonoma PharmaceuticalsOutperform Votes21667.50% Underperform Votes10432.50% Does the media prefer SLRX or SNOA? In the previous week, Salarius Pharmaceuticals' average media sentiment score of 0.00 equaled Sonoma Pharmaceuticals'average media sentiment score. Company Overall Sentiment Salarius Pharmaceuticals Neutral Sonoma Pharmaceuticals Neutral Is SLRX or SNOA more profitable? Salarius Pharmaceuticals has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -35.91%. Sonoma Pharmaceuticals' return on equity of -65.66% beat Salarius Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Salarius PharmaceuticalsN/A -148.63% -110.36% Sonoma Pharmaceuticals -35.91%-65.66%-27.20% Do analysts rate SLRX or SNOA? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Salarius Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/ASonoma Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A Do insiders & institutionals believe in SLRX or SNOA? 11.9% of Salarius Pharmaceuticals shares are held by institutional investors. Comparatively, 2.0% of Sonoma Pharmaceuticals shares are held by institutional investors. 5.5% of Salarius Pharmaceuticals shares are held by insiders. Comparatively, 3.9% of Sonoma Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummarySonoma Pharmaceuticals beats Salarius Pharmaceuticals on 8 of the 13 factors compared between the two stocks. Ad Porter & CompanyRigged election? Porter Stansberry’s viral Breaking Point 2024 broadcast has now been by tens of thousands of Americans who finally understand the grim reality of our next election. With November 5 just around the corner, it’s imperative for your financial future that you read Porter’s message below now and then watch Breaking Point before it’s too late. Watch this video, it is being taken down Monday night Get Salarius Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SLRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLRX vs. The Competition Export to ExcelMetricSalarius PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.09M$6.75B$5.04B$8.43BDividend YieldN/A7.94%7.52%4.16%P/E Ratio-0.1112.17130.2316.67Price / Sales1.13270.431,720.2276.26Price / CashN/A46.0936.9133.54Price / Book0.145.284.604.98Net Income-$12.54M$151.33M$114.94M$224.26M7 Day Performance-13.17%0.30%0.14%1.65%1 Month Performance2.84%14.88%10.15%6.92%1 Year Performance-77.41%36.87%33.87%26.46% Salarius Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLRXSalarius Pharmaceuticals0.5397 of 5 stars$1.45-2.0%N/A-76.0%$2.09M$1.84M-0.1120SNOASonoma Pharmaceuticals0.6131 of 5 stars$2.79+4.1%N/A+1,400.8%$2.57M$12.73M-0.27180Upcoming EarningsMDVLMedAvailN/AN/AN/AN/A$2.91M$43.33M-0.06279Gap DownCDTConduit PharmaceuticalsN/A$0.09flatN/A-93.0%$8.74MN/A0.003Gap DownABVCABVC BioPharmaN/A$0.66-4.3%N/A-43.6%$8.58M$150,000.00-0.4030Gap UpATHEAlterity Therapeutics2.6704 of 5 stars$1.17+1.7%$4.00+241.9%-51.3%$8.55MN/A0.0010SNGXSoligenix0.2162 of 5 stars$3.86+5.2%N/A-49.7%$8.37M$840,000.00-0.4120Upcoming EarningsRNAZTransCode Therapeutics2.244 of 5 stars$0.48+2.1%$3.00+525.0%-96.6%$8.29MN/A0.009UPXIUpexi2.2768 of 5 stars$8.04+2.6%$25.00+210.9%-64.4%$8.19M$80.68M0.00130Gap DownOBSVObsEvaN/AN/AN/AN/A$7.94M$20.11M-0.1150News CoverageCOEPCoeptis TherapeuticsN/A$0.20flatN/A-79.6%$7.87M$80,000.00-0.422Gap Down Related Companies and Tools Related Companies SNOA Competitors MDVL Competitors CDT Competitors ABVC Competitors ATHE Competitors SNGX Competitors RNAZ Competitors UPXI Competitors OBSV Competitors COEP Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SLRX) was last updated on 11/4/2024 by MarketBeat.com Staff From Our Partners2 sentences that change everything you THOUGHT you knew about tradingIf you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfas...Investing Daily | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredElection warning coming true… If you missed it, my emergency election broadcast is now available - watch it before it's too late.Porter & Company | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredA Totally New ‘Income Coin’Buckle up… Because this might shatter everything you thought you knew about "income trading." In fact, i...Crypto 101 Media | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredA new way to play the AI boom (act before November 19)There's a new way to play the $15 trillion AI boom. And it's so simple - you can do it right now with as li...Behind the Markets | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Salarius Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Salarius Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SLRX Stock Alerts